Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.
After an improvement in progression-free survival (PFS) was seen in the phase 3 COMPLEMENT-2 study, the U.S. Food and Drug Administration (FDA) approved approved Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia (CLL).
In the open-label study, the median PFS was 28.9 months with the addition of Arzerra to chemotherapy compared with 18.8 months with fludarabine and cyclophosphamide alone. The overall response rate (ORR) with the triplet was 84 percent versus 68 percent in the control arm, with complete response rates of 27 percent versus 7 percent, respectively.
"This is the fourth CLL indication approved in the United States for Arzerra, and we are pleased to see the availability of this treatment expand to a wider number of patients," Jan van de Winkel, Ph.D., chief executive officer of Genmab, the company developing Arzerra in collaboration with Novartis, said in a statement.
In the phase 3 COMPLEMENT-2 study, 365 patients with relapsed CLL were randomized to receive Arzerra plus fludarabine and cyclophosphamide (183 patients) or fludarabine cyclophosphamide alone (182 patients). Arzerra was administered at 300 mg on day one of the first cycle followed by 1000 mg on day eight. For subsequent cycles, the drug was administered at 1,000 mg on day one. The maximum number of cycles was six in each arm. The chemotherapy agents were given at standard doses.
The median age of patients in the trial was 61 years, with 7 percent over the age of 75. A third of patients had high Rai stage CLL (34 percent) and 69 percent were IGHV unmutated. Seventy-five percent of patients had a chromosomal aberration. The primary endpoint of the study was PFS. Secondary outcome measures focused on overall survival (OS), response, and safety.
Duration of response was 29.6 versus 24.9 months in the Arzerra versus control arms, respectively. Time to progression was also improved with the triplet, at 42.1 months versus 26.8 months.
The time to next cancer therapy was 48.1 months with Arzerra versus 40.1 months in the control arm. Additionally, there was a numerical improvement in median OS with Arzerra at 56.4 months versus 45.8 months with chemotherapy alone; however, the result was not statistically significant.
The adverse event (AE) profile for Arzerra was similar to what has been reported in other trials with the drug. Adverse events reported in 5 percent or more of patients in the Arzerra arm included neutropenia, thrombocytopenia, anemia, nausea, leukopenia, vomiting, pyrexia, rash, fatigue and pneumonia.
The rate of grade 3 or higher AEs with the Arzerra combination was 74 percent, compared with 69 percent in the control arm. Fifty-three percent of patients who received Arzerra had grade 3 or higher neutropenia versus 39 percent of patients who received chemotherapy alone. In the Arzerra cohort, 4 percent of patients had grade 3/4 infusion-related reactions (IRRs) compared with less than 1 percent in the control group. There were no fatalities associated with IRRs.
"There are limited treatment options for patients who have stopped responding to current CLL treatments, which happens in many patients with this disease over time," Tadeusz Robak, M.D., Ph.D., professor of hematology, Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland, said in a statement when the results were presented at the European Hematology Association congress. "These data showed that the addition of ofatumumab to fludarabine and cyclophosphamide extended the amount of time before a patient's CLL progressed, and further add to the body of evidence supporting the potential use of ofatumumab for these patients."
The FDA initially approved Arzerra in 2009 for previously treated patients with CLL that is no longer responding to chemotherapy. In April 2014, the FDA approved Arzerra plus chlorambucil for previously untreated patients with CLL who were considered inappropriate for treatment with fludarabine. In January 2016, the indication for Arzerra was further expanded to include maintenance therapy for patients in complete or partial response following at least two lines of therapy with recurrent or progressive CLL.